Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
View Patent ↗In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or compositions.
1. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a patient in need thereof comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt, thereof, to said patient, wherein said compound is selected from the group consisting of the compounds of the formulas:
2. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a mammal in need thereof, comprising administering to said mammal
an amount of a first compound, or a pharmaceutically acceptable salt thereof; and
an amount of at least one second compound, said second compound being an anti-cancer agent;
wherein the amounts of the first compound and said second compound result in a therapeutic effect, wherein said first compound is selected from the group consisting of the compounds of the formulas:
3. The method of claim 2 , further comprising radiation therapy.
4. The method of claim 2 , wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, liposomal doxorubicin, taxotere, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyl protein transferase inhibitor), BMS 214662 (a farnesyl protein transferase inhibitor), gefitinib, erlotinib, antibodies to EGFR, imatinib, interferon alfa-2b, aramycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, ispinesib, SB-743921, GSK-923295, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestbsterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Trastuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, arsenic trioxide, capecitabine, Vinorelbine, Porfimer, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, cetuximab, satriplatin, Gemtuzumab ozogamicin, bevacizumab, pemetrexed, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and alemtuzamab.
5. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a mammal in need thereof, comprising administering to said mammal
an amount of a first compound, or a pharmaceutically acceptable salt, thereof; and
an amount of temozolomide;
wherein the amounts of the first compound and said temozolomide result in a therapeutic effect, wherein said first compound is selected from the group consisting of the compounds of the formulas:
6. The method of claim 5 , further comprising radiation therapy.
7. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a mammal in need thereof, comprising administering to said mammal a composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of the compounds of the formulas:
8. The method of claim 7 , further comprising administering radiation therapy.
9. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a mammal in need thereof, comprising administering to said mammal a composition comprising (i) a therapeutically effective amount of a first compound, or a pharmaceutically acceptable salt thereof, and (ii) an anti-cancer agent, wherein the amounts of said first compound and anti-cancer agent result in a therapeutic effect, further wherein said first compound is selected from the group consisting of the compounds of the formulas:
10. The method of claim 9 , wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, liposomal doxorubicin Caelyx®, Myocet®, Doxil®, taxotere, taxol, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyl protein transferase inhibitor), BMS 214662 (a farnesyl protein transferase inhibitor), gefitinib, erlotinib, antibodies to EGFR, imatinib, interferon alfa-2b, aramycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, ispinesib, SB-743921, GSK-923295, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Trastuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, arsenic trioxide, Xeloda capecitabine, Vinorelbine, Porfimer, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, cetuximab, satriplatin, Gemtuzumab ozogamicin, bevacizumab, pemetrexed, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and alemtuzamab.
11. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt thereof, to said patient, wherein said compound is selected from the group consisting of the compounds of the formulas:
12. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a patient in need thereof, comprising administering to said patient a composition comprising a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt thereof, to said patient, wherein said compound is selected from the group consisting of the compounds of the formulas:
13. The method of claim 12 , wherein said composition further comprises an anti-cancer agent.
14. The method of claim 12 , further comprising administration of radiation therapy.
15. The method of claim 13 , wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, liposomal doxorubicin, taxotere, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2[-4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyl protein transferase inhibitor), BMS 214662 (a farnesyl protein transferase inhibitor), gefitinib, erlotinib, antibodies to EGFR, imatinib, interferon alfa-2b, aramycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, ispinesib, SB-743921, GSK-923295, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Trastuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, arsenic trioxide, capecitabine, Vinorelbine, Porfimer, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, cetuximab, satriplatin, Gemtuzumab ozogamicin, bevacizumab, pemetrexed, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and alemtuzamab.
16. A composition comprising (i) at least one compound selected from the group consisting of satriplatin, Gemtuzumab ozogamicin, bevacizumab, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and (ii) at least one compound, or a pharmaceutically acceptable salt thereof, wherein said at least one compound in (ii) is selected from the group consisting of the compounds of the formulas:
17. A method of inhibiting a cyclin dependent kinase selected from the group consisting of CDK 1, CDK 2, CDK 5, and CDK 9 in a patient in need thereof, comprising administering the composition of claim 16 to said patient.
18. A method of treating a disease in a patient in need thereof with said composition of claim 16 , wherein said disease is selected from the group consisting of:
Burkett's lymphoma;
chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia.
19. A method of treating a disease in a patient in need thereof with a composition, wherein said disease is selected from the group consisting of: chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia, and further wherein said composition comprises a pharmaceutically acceptable carrier and at least one compound, or a pharmaceutically acceptable salt thereof, wherein said at least one compound is selected from the group consisting of the compounds of the formulas:
20. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a patient in need thereof comprising administering a therapeutically effective amount of a compound of the formula
or a pharmaceutically acceptable salt thereof.